Titre : Dynamine-II

Dynamine-II : Questions médicales fréquentes

Termes MeSH sélectionnés :

Double-Blind Method
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Dynamine-II : Questions médicales les plus fréquentes", "headline": "Dynamine-II : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Dynamine-II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-02-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Dynamine-II" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dynamines", "url": "https://questionsmedicales.fr/mesh/D034281", "about": { "@type": "MedicalCondition", "name": "Dynamines", "code": { "@type": "MedicalCode", "code": "D034281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.990.400" } } }, "about": { "@type": "MedicalCondition", "name": "Dynamine-II", "alternateName": "Dynamin II", "code": { "@type": "MedicalCode", "code": "D034285", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ya-Wen Liu", "url": "https://questionsmedicales.fr/author/Ya-Wen%20Liu", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Center of Precision Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: yawenliu@ntu.edu.tw." } }, { "@type": "Person", "name": "Marc Bitoun", "url": "https://questionsmedicales.fr/author/Marc%20Bitoun", "affiliation": { "@type": "Organization", "name": "Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France." } }, { "@type": "Person", "name": "Adam McCluskey", "url": "https://questionsmedicales.fr/author/Adam%20McCluskey", "affiliation": { "@type": "Organization", "name": "Chemistry, School of Environmental & Life Sciences, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia." } }, { "@type": "Person", "name": "Jessica Laiman", "url": "https://questionsmedicales.fr/author/Jessica%20Laiman", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan." } }, { "@type": "Person", "name": "Hong Cao", "url": "https://questionsmedicales.fr/author/Hong%20Cao", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Preemptive analgesia for hemorrhoidectomy: study protocol for a prospective, randomized, double-blind trial.", "datePublished": "2022-06-27", "url": "https://questionsmedicales.fr/article/35761383", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-022-06107-0" } }, { "@type": "ScholarlyArticle", "name": "Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.", "datePublished": "2023-07-19", "url": "https://questionsmedicales.fr/article/37466211", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/head.14600" } }, { "@type": "ScholarlyArticle", "name": "Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.", "datePublished": "2023-03-28", "url": "https://questionsmedicales.fr/article/36989672", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.schres.2023.03.039" } }, { "@type": "ScholarlyArticle", "name": "Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.", "datePublished": "2023-02-22", "url": "https://questionsmedicales.fr/article/36856701", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1176/appi.ajp.20220737" } }, { "@type": "ScholarlyArticle", "name": "Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.", "datePublished": "2022-12-03", "url": "https://questionsmedicales.fr/article/36462055", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00415-022-11501-4" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Protéines du transport vésiculaire", "item": "https://questionsmedicales.fr/mesh/D033921" }, { "@type": "ListItem", "position": 6, "name": "Dynamines", "item": "https://questionsmedicales.fr/mesh/D034281" }, { "@type": "ListItem", "position": 7, "name": "Dynamine-II", "item": "https://questionsmedicales.fr/mesh/D034285" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Dynamine-II - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Dynamine-II", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Dynamine-II", "description": "Comment diagnostiquer une anomalie de Dynamine-II ?\nQuels tests sont utilisés pour évaluer la Dynamine-II ?\nY a-t-il des marqueurs spécifiques pour la Dynamine-II ?\nQuels symptômes peuvent indiquer un problème avec Dynamine-II ?\nLes tests génétiques sont-ils fiables pour Dynamine-II ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Double-Blind+Method&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Dynamine-II", "description": "Quels sont les symptômes d'une déficience en Dynamine-II ?\nLa Dynamine-II affecte-t-elle le système nerveux ?\nY a-t-il des signes cliniques spécifiques ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on observer des symptômes respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Double-Blind+Method&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Dynamine-II", "description": "Peut-on prévenir les anomalies de Dynamine-II ?\nLe dépistage prénatal est-il possible ?\nLes conseils génétiques sont-ils recommandés ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes habitudes de vie influencent-elles la Dynamine-II ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Double-Blind+Method&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Dynamine-II", "description": "Quels traitements sont disponibles pour les anomalies de Dynamine-II ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider ?\nLa rééducation est-elle bénéfique ?\nY a-t-il des essais cliniques en cours ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Double-Blind+Method&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Dynamine-II", "description": "Quelles complications peuvent survenir avec Dynamine-II ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Double-Blind+Method&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Dynamine-II", "description": "Quels sont les facteurs de risque pour les anomalies de Dynamine-II ?\nL'âge joue-t-il un rôle dans les anomalies de Dynamine-II ?\nY a-t-il des prédispositions génétiques ?\nLes facteurs environnementaux influencent-ils ?\nLes habitudes de vie affectent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D034285?mesh_terms=Double-Blind+Method&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de Dynamine-II ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de protéines peuvent être utilisés pour diagnostiquer." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer la Dynamine-II ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'immunoblotting et la microscopie électronique pour visualiser les anomalies." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour la Dynamine-II ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de marqueurs spécifiques largement reconnus pour la Dynamine-II." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec Dynamine-II ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes neurologiques ou musculaires peuvent indiquer une anomalie de Dynamine-II." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils fiables pour Dynamine-II ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent fournir des informations précises sur les mutations de Dynamine-II." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en Dynamine-II ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent faiblesse musculaire, troubles de la coordination et problèmes neurologiques." } }, { "@type": "Question", "name": "La Dynamine-II affecte-t-elle le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies de Dynamine-II peuvent entraîner des troubles neurologiques significatifs." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques spécifiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'atrophie musculaire et des réflexes anormaux peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la déficience." } }, { "@type": "Question", "name": "Peut-on observer des symptômes respiratoires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des problèmes respiratoires peuvent survenir en raison de la faiblesse musculaire." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies de Dynamine-II ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de méthodes de prévention connues pour les anomalies de Dynamine-II." } }, { "@type": "Question", "name": "Le dépistage prénatal est-il possible ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage prénatal peut être envisagé si des antécédents familiaux sont présents." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques associés." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis pour Dynamine-II." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles la Dynamine-II ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuves solides que les habitudes de vie influencent directement Dynamine-II." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies de Dynamine-II ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont principalement symptomatiques et peuvent inclure la physiothérapie." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais n'est pas encore une option standard pour Dynamine-II." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent aider à gérer les symptômes, mais aucun n'est spécifique à Dynamine-II." } }, { "@type": "Question", "name": "La rééducation est-elle bénéfique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation physique peut améliorer la force et la coordination chez les patients." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques en cours ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent de nouvelles approches thérapeutiques pour Dynamine-II." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Dynamine-II ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles moteurs, des problèmes respiratoires et des infections." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent avoir un risque accru de maladies neuromusculaires associées." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies de Dynamine-II ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de maladies génétiques sont un facteur de risque majeur." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans les anomalies de Dynamine-II ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer l'apparition des symptômes, mais n'est pas un facteur de risque direct." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations spécifiques dans le gène de la Dynamine-II peuvent prédisposer aux anomalies." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, l'impact des facteurs environnementaux sur Dynamine-II n'est pas bien compris." } }, { "@type": "Question", "name": "Les habitudes de vie affectent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuves solides que les habitudes de vie influencent le risque de Dynamine-II." } } ] } ] }

Sources (10000 au total)

Preemptive analgesia for hemorrhoidectomy: study protocol for a prospective, randomized, double-blind trial.

Hemorrhoidectomy is associated with intense postoperative pain that requires multimodal analgesia. It includes nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and local anesthetics to re... Patients of our clinic who meet the following inclusion criteria are included: hemorrhoids grade III-IV and the planned Milligan-Morgan hemorrhoidectomy. After signing the consent all participants are... Multimodality pain management has been shown to improve pain control and decrease opioid intake in patients after hemorrhoidectomy in several studies. Gabapentin can be considered as an alternative ap... ClinicalTrial.gov NCT04361695 . Registered on April 24, 2020, version 1.0....

Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.

Melatonin is effective for migraine prevention in adults. We hypothesized that melatonin would also be effective for migraine prevention in children and adolescents.... This was a randomized, double-blind trial of melatonin (3 mg or 6 mg) versus placebo for migraine prevention in 10-17 year-olds with 4-28/28 headache days at baseline. Participants were recruited from... The study closed early due to slow enrollment (n = 72). Two participants were in the single-blind phase when the study closed, therefore the meaningful n = 70. Sixteen percent (11/70) were lost to fol... When compared to recall at enrollment, headache days decreased across the single-blind placebo phase and the double-blind phase. There was no suggestion of superiority of melatonin; however, given the...

Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.

Noradrenergic imbalance in the brain of schizophrenia patients may underlie both symptomatology and deficits in basic information processing. The current study investigated whether augmentation with t... In a double-blind placebo-controlled randomized clinical trial, 32 chronic schizophrenia patients were randomly assigned to six-weeks augmentation with either 50 μg clonidine or placebo to their curre... Only patients treated with clonidine showed significantly reduced PANSS negative, general and total scores at follow-up compared to baseline. On average, also patients treated with placebo showed mino... Only patients treated with clonidine showed a significant decrease on two out of the three PANSS subscales, while additionally retained their levels of sensorimotor gating. Given that there are only a...

Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.

Trichotillomania and skin-picking disorder are underrecognized and often disabling conditions in which individuals repeatedly pull at their hair or pick at their skin, leading to noticeable hair loss ... One hundred adults with trichotillomania or skin-picking disorder (86 women; mean age, 31.4 years [SD=10.2]) were enrolled in a double-blind trial of memantine (dosing range, 10-20 mg/day) or placebo ... Compared with placebo, memantine treatment was associated with significant improvements in scores on the NIMH scale, Sheehan Disability Scale, and Clinical Global Impressions severity scale in terms o... This study found that memantine treatment resulted in statistically significant reductions in hair pulling and skin-picking symptoms compared with placebo, with relatively high efficacy (based on numb...

Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.

Friedreich ataxia is (FRDA) an autosomal recessive neurodegenerative disorder associated with intrinsic oxidative damage, suggesting that decreasing lipid peroxidation (LPO) might ameliorate disease p... Sixty-five subjects were recruited across six sites and received either placebo or active drug for an 11-month study. Subjects were evaluated at 0, 4, 9, and 11 months, with the primary outcome measur... Forty-five subjects completed the protocol. RT001 was well tolerated, with no serious adverse events related to drug. Plasma and red blood cell (RBC) membrane levels of D2-LA and its primary metabolit... The results of this study provide no evidence for a significant benefit of RT001 at the dosages tested in this Friedreich ataxia patient population....

The effect of bromelain in periodontal surgery: a double-blind randomized placebo-controlled trial.

Periodontitis is a persistent inflammatory condition. Eliminating the infection and reducing its risk factors are the first steps in treating periodontitis. When the anti-infective therapy is complete... This double-blind randomized placebo-controlled trial included 28 candidates for pocket elimination surgery referred to the private office of a periodontist in Bandar Abbas, Iran, from April 18 to Aug... Four weeks after intervention, BOP was significantly lower with Anaheal compared to placebo (0% vs. 35.7%, P = 0.014). However, there was no significant difference in GI between groups (P = 0.120). Me... One-week treatment with Anaheal at a dose of 1 g/d after pocket elimination surgery resulted in significantly lower BOP compared to placebo.... Iranian Registry of Clinical Trials (IRCT), IRCT20201106049289N1. Registered 06/04/2021. Registered prospectively, https://www.irct.ir/trial/52181 ....

Topical Tranexamic Acid in Breast Reconstruction: A Double-Blind Randomized Controlled Trial.

Excess fluid accumulation (seroma/hematoma) around the breast implant after reconstruction can lead to significant complications. Topical administration of tranexamic acid (TXA) may reduce fluid accum... This paired, double-blind, randomized, controlled trial enrolled patients undergoing bilateral mastectomies with immediate direct-to-implant reconstruction. In each patient, one breast was randomized ... Fifty-three eligible patients, representing 106 breasts, were enrolled. All patients underwent bilateral nipple-sparing mastectomies. After randomization, TXA was placed in the right breast in 30 pati... Soaking the mastectomy bed with 3% topical TXA before implant insertion leads to a decrease in drain output and a decrease in complications. Topical administration of TXA represents an option to decre... Therapeutic, I....

Oral lactase for infantile colic: a randomized double-blind placebo-controlled trial.

Infantile colic is a common problem during the first three months of life. This randomized, double-blind, placebo-controlled trial conducted in an urban hospital in Delhi, India evaluated the efficacy... One hundred sixty-two clinically healthy infants aged < 5 months age [mean (SD) = 63.5 (30.5) days] fulfilling the Rome-IV diagnostic criteria for infantile colic were enrolled. Eligible children were... At the end of four weeks, mean (SD) crying or fussing time (min/d) was significantly shorter in infants receiving lactase in comparison to placebo [89.9 (115.2) vs.178.5 (153.2); P = 0.001]. The mean ... Oral lactase treatment in infantile colic results in symptomatic relief in terms of shortening of duration of crying or fussing, and better parental satisfaction.... Clinical trial registry of India (CTRI/2017/12/010930) registered on 20/12/2017....

Use of Tranexamic Acid in Liposculpture: A Double-Blind, Multicenter, Randomized Clinical Trial.

Intraoperative hemostasis should be performed with great caution because bleeding is a huge enemy of patient safety during surgery. Tranexamic acid is a lysine synthetic derivate that inhibits fibrino... The authors conducted a multicenter, double-blind, randomized, controlled clinical trial in patients who were scheduled for liposculpture in three plastic surgery centers (Colombia and Mexico) between... The authors found the intravenous intervention group to have a greater hemoglobin level than the other two groups on both the first postoperative day ( p = 0.0001) and the fifth postoperative day ( p ... Intravenous tranexamic acid is a good therapeutic choice to implement on liposculpture procedures to decrease postoperative bleeding.... The preoperative use of intravenous tranexamic acid not only decreases the bleeding rate after liposuction procedures, but also allows greater lipoaspirate volumes when performing high-definition lipo... Therapeutic, I....